Otsuka Pharmaceutical has entered into a worldwide exclusive license agreement with Osaka University for for receptor T cell (CART) therapy (MMG 49 CAR-T cell therapy). MMG49 is a chimeric antigen targeted to active integrin β7 found in multiple myeloma.

Otsuka Pharma news release, August 21, 2018